Market Exclusivity for Drugs with Multiple Orphan Approvals (1983 –2017) and Associated Budget Impact in the US
ConclusionsMultiple blockbuster drugs have received exclusivity of > 10 years through theOrphan Drug Act, thereby delaying rare disease cohorts ’ access to generic/biosimilar equivalents.
Source: PharmacoEconomics - Category: Health Management Source Type: research
More News: Health Management | Rare Diseases